These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 1638933

  • 1. Cytopathology of malignant mesothelioma: a stepwise logistic regression analysis.
    Stevens MW, Leong AS, Fazzalari NL, Dowling KD, Henderson DW.
    Diagn Cytopathol; 1992; 8(4):333-41. PubMed ID: 1638933
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Immunocytochemistry in the differential diagnosis of serous effusions: a comparative evaluation of eight monoclonal antibodies in Papanicolaou stained smears.
    Lozano MD, Panizo A, Toledo GR, Sola JJ, Pardo-Mindán J.
    Cancer; 2001 Feb 25; 93(1):68-72. PubMed ID: 11241268
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Utility of HBME-1 immunostaining in serous effusions.
    Ascoli V, Carnovale-Scalzo C, Taccogna S, Nardi F.
    Cytopathology; 1997 Oct 25; 8(5):328-35. PubMed ID: 9313985
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry.
    Su XY, Li GD, Liu WP, Xie B, Jiang YH.
    Diagn Cytopathol; 2011 Dec 25; 39(12):900-8. PubMed ID: 20836004
    [Abstract] [Full Text] [Related]

  • 8. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.
    Politi E, Kandaraki C, Apostolopoulou C, Kyritsi T, Koutselini H.
    Diagn Cytopathol; 2005 Mar 25; 32(3):151-5. PubMed ID: 15690338
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Ber-EP4 for differentiating adenocarcinoma from reactive and neoplastic mesothelial cells in serous effusions. Comparison with carcinoembryonic antigen, B72.3 and Leu-M1.
    Bailey ME, Brown RW, Mody DR, Cagle P, Ramzy I.
    Acta Cytol; 1996 Mar 25; 40(6):1212-6. PubMed ID: 8960030
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Calretinin. A selective marker of normal and neoplastic mesothelial cells in serous effusions.
    Barberis MC, Faleri M, Veronese S, Casadio C, Viale G.
    Acta Cytol; 1997 Mar 25; 41(6):1757-61. PubMed ID: 9390137
    [Abstract] [Full Text] [Related]

  • 16. Diagnostic problems in serous effusions.
    Bedrossian CW.
    Diagn Cytopathol; 1998 Aug 25; 19(2):131-7. PubMed ID: 9702493
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Quantitative ultrastructural study of nuclei from exfoliated benign and malignant mesothelial cells and metastatic adenocarcinoma cells.
    Dardick I, Butler EB, Dardick AM.
    Acta Cytol; 1986 Aug 25; 30(4):379-84. PubMed ID: 3461648
    [Abstract] [Full Text] [Related]

  • 20. Distinction between cells in serous effusions using a panel of antibodies.
    Lauritzen AF.
    Virchows Arch A Pathol Anat Histopathol; 1987 Aug 25; 411(3):299-304. PubMed ID: 2441518
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.